Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

105.06 +2.43 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
65 66 Next >
Analyzing NYSE:NVO's Dividend Potential.
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) provides a good dividend, while having solid fundamentals. 
Via Chartmill
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
Billionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks
The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Viking Therapeutics Incredibly Undervalued?
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound. 
Via The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence. 
Via The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock. 
Via Chartmill
Why Novo Nordisk Topped the Market Today
It's not only spending its capital on developing new drugs. 
Via The Motley Fool
MarketBeat Week in Review – 4/22 - 4/26
Investors continue to look for clarity as tech earnings sent stocks higher to end the week, even as investors hope for rate cuts fade as inflation rises 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could... 
Via Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
Via InvestorPlace
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Lilly recently announced news that could solve a big problem. 
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth. 
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits. 
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
These stocks probably won't be getting much cheaper. 
Via The Motley Fool
MarketBeat Week in Review – 4/15 - 4/19
The markets continued to move lower ahead of a big earnings week as analysts adjust valuations on the outlook for interest rates and geopolitical concerns 
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
3 Biotech Stocks Set to Double by 2028
These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains. 
Via InvestorPlace
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk. 
Via The Motley Fool
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic... 
Via Benzinga
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025. 
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals. 
Via The Motley Fool
Powell And The Great Indecision
In today’s presser, Powell basically said what he typically says. Higher for longer but maybe not as risks remain to the economy while inflation is too sticky. 
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.